

# PROVIDER QUICK POINTS

## PROVIDER INFORMATION



September 28, 2018

### Pharmacy Benefit Exclusion for Azedra® (iobenguane I 131) Intravenous (IV) Injection

Blue Cross and Blue Shield of Minnesota and Blue Plus (Blue Cross) is committed to providing subscribers with safe, quality, pharmacy care.

Azedra® (iobenguane I 131) IV injection is a new radiopharmaceutical product approved by the Food and Drug Administration (FDA) for the treatment of adults and adolescents age 12 years and older with rare tumors of the adrenal gland (pheochromocytoma or paraganglioma) that cannot be surgically removed, have spread beyond the original tumor site and require systemic anticancer therapy. This is the first FDA-approved drug for this use. Upon launch, Azedra® (iobenguane I 131) will be excluded from pharmacy benefit coverage due to clinician-administered route of administration. Azedra® (iobenguane I 131) may be available for medical benefit coverage for subscribers who are eligible.

Drug Name
Azedra® (iobenguane I 131) IV injection

#### Products Impacted

This notice applies to the following Minnesota Health Care Programs:

- Blue Advantage Prepaid Medical Assistance Program (PMAP)
- MinnesotaCare (MNCare)
- Minnesota Senior Care Plus (MSC+)

#### Questions?

If you have questions, please contact provider services at **(651) 662-5200** or **1-800-262-0820**.

QP82-18

Distribution: Available on providers.bluecrossmn.com. <https://www.bluecrossmn.com/healthy/public/personal/home/providers/forms-and-publications>

Blue Cross® and Blue Shield® of Minnesota and Blue Plus® are nonprofit independent licensees of the Blue Cross and Blue Shield Association.

L264R03 (12/13)